FMP
Forte Biosciences, Inc.
FBRX
NASDAQ
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
19.34 USD
0.68 (3.52%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Paul A. Wagner Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.fortebiorx.comexchange
NASDAQ
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
CIK
0001419041
ISIN
US34962G1094
CUSIP
34962G109
Address
3060 Pegasus Park Drive
Phone
310 618 6994
Country
US
Employee
11
IPO Date
Apr 13, 2017
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
FBRX Financial Summary
CIK
0001419041
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
34962G109
ISIN
US34962G1094
Country
US
Price
19.34
Beta
1.46
Volume Avg.
542.32k
Market Cap
28.27M
Shares
-
52-Week
4.11-28.68
DCF
9.47
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.18
P/B
-
Website
https://www.fortebiorx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest FBRX News
It looks like there's no news available.
